Core Viewpoint - The Hong Kong stock market saw significant net buying from Northbound capital, totaling HKD 94.85 billion on August 6, with Tencent, Alibaba, and SMIC being the most favored stocks, while Xiaomi faced the highest net selling pressure [1][2]. Group 1: Northbound Capital Activity - Northbound capital recorded a net buying of HKD 94.85 billion, with HKD 44.69 billion from the Shanghai Stock Connect and HKD 50.16 billion from the Shenzhen Stock Connect [1]. - The top net buying stocks included Tencent (00700), Alibaba-W (09988), and SMIC (00981) [1]. - Xiaomi Group-W (01810) experienced the highest net selling, amounting to HKD 2.29 billion [6]. Group 2: Individual Stock Performance - Tencent Holdings (00700) had a net inflow of HKD 7.18 billion, driven by positive market sentiment regarding its upcoming mobile game "无畏契约," which has over 50 million pre-registrations [4][5]. - Alibaba-W (09988) saw a net inflow of HKD 6.78 billion, following the launch of a new membership system that integrates various services across its platforms [5]. - SMIC (00981) recorded a net inflow of HKD 3.64 billion, with expectations of a revenue decline in Q2 but positioned as a core beneficiary of high-end replacements [5][6]. - Crystal Technology (02228) gained a net inflow of HKD 5.32 billion due to a significant partnership with DoveTree for drug development [6]. - Ideal Auto-W (02015) had a net inflow of HKD 1.58 billion after announcing adjustments to its vehicle configurations based on user feedback [6].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康方生物科技（開曼）有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09926 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,0 ...

8月6日消息，南向资金今日成交1259.74亿港元，净流入约94.85亿港元。其中沪港股通净流入约44.69亿 港元，深港股通净流入约50.16亿港元 交易所数据显示，8月6日南向资金动向： 大幅净买入：腾讯控股(00700.HK)15.18亿港元、阿里巴巴-W(09988.HK)8.76亿港元、中芯国际 (00981.HK)6.12亿港元、晶泰控股(02228.HK)5.33亿港元、康方生物(09926.HK)1.38亿港元、理想汽车- W(02015.HK)1.19亿港元。 晶泰控股今日涨12.42%，沪港股通净买入4.75亿港元，深港股通净买入5750.15万港元。 康方生物今日涨5.03%，深港股通净买入1.38亿港元。 理想汽车W今日跌5.35%，沪港股通净买入1.58亿港元，深港股通净卖出3918.97万港元。 小米集团W今日跌0.55%，沪港股通净卖出8501.64万港元，深港股通净卖出14410.94万港元。 泡泡玛特今日涨7.87%，沪港股通净卖出31306.92万港元，深港股通净买入8996.36万港元。 美团W今日跌1.46%，沪港股通净买入2.37亿港元，深港股通净卖出38412.99 ...

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound trading, with a total net buy of 94.85 billion HKD on August 6, 2023, indicating strong investor interest in certain stocks, particularly Tencent, Alibaba, and SMIC, while Xiaomi faced notable net selling [1][4]. Group 1: Northbound Trading Activity - Northbound trading through Stock Connect saw a net buy of 44.69 billion HKD from Shanghai and 50.16 billion HKD from Shenzhen [1]. - The most bought stocks included Tencent (00700), Alibaba-W (09988), and SMIC (00981) [1]. - Xiaomi Group-W (01810) was the most sold stock, with a net sell of 2.29 billion HKD [6]. Group 2: Individual Stock Performance - Tencent Holdings (00700) had a net buy of 26.36 billion HKD, with total trading volume of 45.54 billion HKD, reflecting a net inflow of 7.18 billion HKD [2]. - Alibaba-W (09988) saw a net buy of 19.21 billion HKD, with total trading volume of 31.64 billion HKD, resulting in a net inflow of 6.78 billion HKD [2]. - SMIC (00981) recorded a net buy of 13.47 billion HKD, with a total trading volume of 23.30 billion HKD, leading to a net inflow of 3.64 billion HKD [2]. Group 3: Company-Specific News - Tencent's new mobile game "无畏契约" is anticipated to generate annual revenue of 5 to 6 billion CNY, with over 50 million pre-registrations [4]. - Alibaba launched a new membership system integrating various services, marking a strategic shift towards a comprehensive consumer platform [5]. - SMIC is expected to report a quarterly revenue decline for the first time in two years, with a guidance range of 4% to 6% [5]. - Crystal Technology (02228) secured a record order of approximately 470 billion HKD (59.9 billion USD) for drug development collaboration [6].

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 74.86%, Green Power Environmental (01330) at 70.22%, and China Shenhua (01088) at 67.10% [1] - The largest increases in holding amounts over the last five trading days were seen in the following companies: Yingfu Fund (02800) with +5.886 billion, Hang Seng China Enterprises (02828) with +4.157 billion, and Li Auto-W (02015) with +2.947 billion [2] - The largest decreases in holding amounts over the last five trading days were recorded for Kangfang Biopharmaceutical (09926) with -0.774 billion, HSBC Holdings (00005) with -0.523 billion, and China Hongqiao (01378) with -0.506 billion [3] Group 1: Top Holding Ratios - China Telecom (00728) holds 10.39 billion shares, representing 74.86% of its total [1] - Green Power Environmental (01330) holds 0.284 billion shares, representing 70.22% of its total [1] - China Shenhua (01088) holds 2.266 billion shares, representing 67.10% of its total [1] Group 2: Recent Increases in Holdings - Yingfu Fund (02800) saw an increase of +5.886 billion in holding amount, with a change of +23.21079 million shares [2] - Hang Seng China Enterprises (02828) increased by +4.157 billion, with a change of +4.54198 million shares [2] - Li Auto-W (02015) increased by +2.947 billion, with a change of +2.86721 million shares [2] Group 3: Recent Decreases in Holdings - Kangfang Biopharmaceutical (09926) experienced a decrease of -0.774 billion, with a change of -0.47511 million shares [3] - HSBC Holdings (00005) saw a decrease of -0.523 billion, with a change of -0.54260 million shares [3] - China Hongqiao (01378) decreased by -0.506 billion, with a change of -2.37590 million shares [3]

Market Overview - US stock indices rebounded, influenced positively by Trump's market support, leading to a 0.68% rise in Hong Kong stocks [1] - San Francisco Fed President Daly indicated that the timing for interest rate cuts is approaching, with expectations for two 25 basis point cuts this year [1] - Goldman Sachs predicts three consecutive 25 basis point cuts starting in September, with a potential 50 basis point cut if unemployment rises further [1] Domestic Market Sentiment - A-share new account openings in July reached 1.96 million, a 71% year-on-year increase, indicating rising domestic confidence [2] - The stock of Upwind New Materials surged 20% after resuming trading, reigniting market enthusiasm [2] - The steel sector saw a significant rise, with Maanshan Iron & Steel's stock increasing over 15% due to improved loss forecasts and supportive policies [2] Industry Trends - The paper industry is experiencing a price increase, with major companies like Nine Dragons Paper and Lee & Man Paper announcing price hikes [2] - The eleventh batch of centralized drug procurement in China saw a record 45 companies applying for the same drug, intensifying competition in the generic drug market [3] - Investment is shifting towards innovative drugs, with companies like Junshi Biosciences seeing stock increases of nearly 34% due to promising clinical trials [3] Financial Support for Key Industries - A joint guideline from the central bank and seven departments aims to support financing for key manufacturing sectors, including integrated circuits and medical equipment [4] - AI-related companies like Longi Green Energy and Lenovo's server business are seeing stock increases due to new orders and market interest [4] Gaming Industry Performance - The domestic gaming market is projected to reach RMB 168 billion in sales by the first half of 2025, a 14.08% year-on-year increase [4] - Heartbeat Games anticipates a revenue increase of approximately 37% for the first half of 2025, driven by strong performance from self-developed games [4] Individual Company Highlights - Tencent's mobile game "Valorant: Source Action" is set to launch on August 19, with projected annual revenue exceeding RMB 6 billion [5] - Oriental Selection's stock surged nearly 17% ahead of its upcoming financial report, reflecting strong market performance [6] - The Macau gaming sector is experiencing a positive trend, with Morgan Stanley raising its revenue growth forecast for the year from 5% to 10% [6] Technological Advancements - Apple's breakthrough in brain-computer interface (BCI) technology allows users to control devices through thought, indicating a significant market opportunity [7] - The Chinese BCI market is expected to exceed RMB 3.8 billion by 2025, with a CAGR of approximately 20% [7] Investment Opportunities - Kelun-Bio has become a top holding in a major fund, indicating strong market confidence in its innovative drug pipeline [8] - The company has established multiple technology platforms and is expected to accelerate commercialization in 2025 [8]

Market Overview - On August 5, the Hang Seng Index rose by 0.68%, with total southbound trading amounting to HKD 129.701 billion, including buy transactions of HKD 76.563 billion and sell transactions of HKD 53.138 billion, resulting in a net buy of HKD 23.426 billion [1] Southbound Trading Details - The southbound trading through Stock Connect (Shenzhen) had a total trading amount of HKD 47.198 billion, with buy transactions of HKD 28.343 billion and sell transactions of HKD 18.854 billion, leading to a net buy of HKD 9.489 billion [1] - The southbound trading through Stock Connect (Shanghai) had a total trading amount of HKD 82.504 billion, with buy transactions of HKD 48.220 billion and sell transactions of HKD 34.284 billion, resulting in a net buy of HKD 13.936 billion [1] Active Stocks - The most actively traded stock by southbound funds was the Tracker Fund of Hong Kong, with a total trading amount of HKD 6.3006 billion and a net buy of HKD 6.2929 billion, closing with a price increase of 0.63% [1] - Tencent Holdings and SMIC followed, with trading amounts of HKD 4.898 billion and HKD 3.569 billion, respectively [1] - A total of 12 stocks experienced net buying, with Tencent Holdings seeing a net buy of HKD 0.832 billion and Southern Hang Seng Technology a net buy of HKD 0.798 billion [1] Continuous Net Buying - Among the stocks, Tencent Holdings, Xiaomi Group-W, and Kuaishou-W were continuously net bought for more than three days, with Tencent Holdings leading with a total net buy of HKD 4.426 billion over nine days [2] - Xiaomi Group-W followed closely with a net buy of HKD 4.411 billion over eight days, and Kuaishou-W with HKD 2.452 billion over four days [2] Summary of Active Stocks on August 5 - The following table summarizes the active stocks and their respective trading amounts, net buying, and daily price changes: | Code | Name | Trading Amount (HKD million) | Net Buy (HKD million) | Daily Change (%) | |--------|--------------------|------------------------------|-----------------------|-------------------| | 02800 | Tracker Fund | 6300.64 | 6292.99 | 0.63 | | 00700 | Tencent Holdings | 4897.79 | 831.72 | 1.64 | | 03033 | Southern Hang Seng Tech | 868.05 | 798.36 | 0.93 | | 01024 | Kuaishou-W | 2408.49 | 646.71 | 2.79 | | 02015 | Li Auto-W | 2927.53 | 586.03 | 1.58 | | 09988 | Alibaba-W | 3391.32 | 511.50 | -0.17 | | 01357 | Meituan | 2976.58 | 386.43 | -6.92 | | 09926 | CanSino Biologics | 877.47 | 290.20 | 7.17 | | 03690 | Meituan-W | 901.74 | 270.26 | -0.08 | | 01810 | Xiaomi Group-W | 2887.14 | 248.22 | -0.46 | | 02577 | InnoCare Pharma | 2303.82 | 232.89 | -6.65 | | 00981 | SMIC | 3568.78 | 121.27 | -0.97 | | 01788 | Guotai Junan International | 2225.67 | -5.07 | -0.94 | [2]

Core Viewpoint - The Hong Kong stock market is experiencing a strong performance, particularly in the innovative pharmaceutical sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) leading the gains, reflecting a growing interest and activity in this industry [1][6]. Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened strong and rose by 2.73%, closing above the 5-day moving average with a trading volume exceeding 800 million yuan [1][2]. - Among the 30 constituent stocks in the innovative drug sector, 22 stocks increased by over 2%, with notable gains from companies like Lepu Biopharma-B, Ascentage Pharma-B, and CanSino Biologics-B, which saw double-digit increases [1][4]. Key Stocks - Kangfang Biotech surged over 7%, reaching a historical high, following the initiation of a global Phase III clinical trial for its dual-target drug, Ivosidenib [3]. - Innovent Biologics rose over 6%, benefiting from a report by JPMorgan highlighting the importance of business development (BD) in the biopharmaceutical sector this year [3]. - 3SBio Inc. increased by 5.97%, with recent announcements regarding a share placement to Pfizer, raising approximately 785 million HKD for clinical and preclinical projects [3]. Industry Growth - The National Medical Products Administration reported that 43 innovative drugs were approved in the first half of the year, a 59% increase year-on-year, nearing the total of 48 approvals expected for the entire year of 2024 [4]. - The innovative drug sector is entering a phase of significant technological advancements, with domestic companies increasingly leading innovation rather than merely following trends [5]. Policy Support - Recent favorable policies from the National Healthcare Security Administration include a price stabilization mechanism for newly launched drugs, which aims to prevent immediate price reductions upon market entry [5]. - Analysts from China International Capital Corporation express optimism about the long-term development of the innovative drug industry, supported by a favorable regulatory environment and abundant clinical resources [5]. ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) is the first ETF to track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry chain [6]. - Year-to-date, the index has increased by 101.58%, significantly outperforming the Hang Seng Index and the Hang Seng Tech Index [8].

深港通（南向）十大活跃成交公司 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 腾讯控股(00700) | 19.54 亿元 | +3.05 亿元 | | 小米集团-W(01810) | 13.14 亿元 | +244.56 万元 | | 中芯国际(00981) | 12.65 亿元 | +2.74 亿元 | | 理想汽车-W(02015) | 12.52 亿元 | +3.00 亿元 | | 阿里巴巴-W(09988) | 12.19 亿元 | +2.55 亿元 | | 美图公司(01357) | 11.05 亿元 | +2.67 亿元 | | 快手-W(01024) | 9.07 亿元 | +3.05 亿元 | | 美团-W(03690) | 9.02 亿元 | +2.70 亿元 | | 康方生物(09926) | 8.77 亿元 | +2.90 亿元 | | 南方恒生科技(03033) | 8.68 亿元 | +7.98 亿元 | 智通财经APP获悉，2025年8月5日当天，盈富基金(02800)、腾讯控股(00700)、英诺赛科(02577)位居沪 港通（南向） ...

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound trading, indicating a positive sentiment among investors towards certain stocks and sectors, particularly technology and ETFs [1][6]. Group 1: Northbound Trading Activity - Northbound trading recorded a net buy of HKD 234.26 billion, with HKD 139.36 billion from the Shanghai Stock Connect and HKD 94.89 billion from the Shenzhen Stock Connect [1]. - The most purchased stocks included the Tracker Fund of Hong Kong (盈富基金, 02800), Tencent (00700), and the Southern Hang Seng Technology ETF (南方恒生科技, 03033) [1][6]. - The stock with the highest net sell was Guotai Junan International (国泰君安国际, 01788), with a net outflow of HKD 50.72 million [1][9]. Group 2: Individual Stock Performance - The Tracker Fund of Hong Kong (02800) saw a net inflow of HKD 62.93 billion, while Tencent (00700) had a net inflow of HKD 5.26 billion [2]. - Other notable net inflows included InnoCare Pharma (英诺赛科, 02577) with HKD 2.33 billion, and Alibaba (阿里巴巴-W, 09988) with HKD 2.57 billion [2][8]. - Li Auto (理想汽车-W, 02015) received a net inflow of HKD 5.86 billion following an announcement of configuration adjustments for its i8 model [7]. Group 3: Sector Insights - The technology sector, which constitutes nearly one-third of the Hong Kong market, is expected to undergo a revaluation driven by improving fundamentals and policy expectations [6]. - Companies like Meitu (美图公司, 01357) reported a projected net profit increase of 65% to 72% year-on-year, indicating strong operational performance [7]. - UBS highlighted the potential of Akeso's core product AK112 in various cancer treatments, projecting significant revenue contributions from upcoming clinical trials [8].